Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics (OTCQB: RVVTF) provided an update on their research study evaluating Bucillamine as a potential treatment for nerve agent exposure, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC). The first set of animal trials, including soman controls and bucillamine pretreated subjects, has been completed, with DRDC now analyzing GABA receptor downregulation data.
If the results prove significant, Revive and DRDC will discuss future development paths. Promising outcomes could lead to further studies for FDA and Health Canada approvals for Bucillamine's use in treating nerve agent or organophosphate pesticide poisoning, as well as exploring its potential for traumatic brain injury from concussive forces and viral infections.
Bucillamine, being a more effective antioxidant than n-acetylcysteine (NAC), could potentially provide increased efficacy against seizure activity while reducing anticoagulant and bleeding event risks associated with NAC. The research focuses on neuroprotection of GABA(A) receptors, important for current anticonvulsant therapies.
Revive Therapeutics (OTCQB: RVVTF) ha fornito un aggiornamento sul loro studio di ricerca che valuta Bucillamina come potenziale trattamento per l'esposizione agli agenti nervini, condotto in collaborazione con il Defence R&D Canada – Suffield Research Centre (DRDC). Il primo insieme di prove sugli animali, che includeva controlli su soman e soggetti pretrattati con bucillamina, è stato completato, con il DRDC che ora analizza i dati sulla downregulation dei recettori GABA.
Se i risultati si rivelano significativi, Revive e DRDC discuteranno delle future vie di sviluppo. Risultati promettenti potrebbero portare a ulteriori studi per le approvazioni della FDA e di Health Canada per l'uso della Bucillamina nel trattamento dell'intossicazione da agenti nervini o pesticidi organofosforici, oltre a esplorare il suo potenziale per il danno cerebrale traumatico causato da forze concussive e infezioni virali.
Bucillamina, essendo un antiossidante più efficace della n-acetilcisteina (NAC), potrebbe fornire un'efficacia maggiore contro l'attività convulsiva, riducendo al contempo i rischi di eventi emorragici e anticoagulanti associati alla NAC. La ricerca si concentra sulla neuroprotezione dei recettori GABA(A), importanti per le attuali terapie anticonvulsivanti.
Revive Therapeutics (OTCQB: RVVTF) proporcionó una actualización sobre su estudio de investigación que evalúa Bucillamina como un tratamiento potencial para la exposición a agentes nerviosos, realizado en asociación con el Defence R&D Canada – Suffield Research Centre (DRDC). El primer conjunto de ensayos en animales, que incluye controles de soman y sujetos pretratados con bucillamina, se ha completado, y ahora el DRDC está analizando los datos sobre la downregulation de los receptores GABA.
Si los resultados son significativos, Revive y DRDC discutirán futuras vías de desarrollo. Resultados prometedores podrían llevar a estudios adicionales para obtener aprobaciones de la FDA y de Health Canada para el uso de Bucillamina en el tratamiento de la intoxicación por agentes nerviosos o pesticidas organofosforados, así como explorar su potencial para lesiones cerebrales traumáticas causadas por fuerzas conmocionantes e infecciones virales.
Bucillamina, siendo un antioxidante más efectivo que la n-acetilcisteína (NAC), podría ofrecer una mayor eficacia contra la actividad convulsiva, al mismo tiempo que reduce los riesgos de eventos hemorrágicos y anticoagulantes asociados con la NAC. La investigación se centra en la neuroprotección de los receptores GABA(A), que son importantes para las terapias anticonvulsivantes actuales.
Revive Therapeutics (OTCQB: RVVTF)는 부실라민을 신경 작용제 노출에 대한 잠재적 치료제로 평가하는 연구 연구에 대한 업데이트를 제공했습니다. 이 연구는 캐나다 방위 연구 개발 - suffield 연구 센터 (DRDC)와 협력하여 진행되었습니다. 소만 대조군 및 부실라민 사전 치료를 받은 피험자를 포함한 첫 번째 동물 시험 세트가 완료되었으며, 현재 DRDC는 GABA 수용체 다운레귤레이션 데이터를 분석하고 있습니다.
결과가 중요하다면 Revive와 DRDC는 향후 개발 경로에 대해 논의할 것입니다. 유망한 결과는 부실라민의 사용을 FDA 및 캐나다 보건청에 승인 받기 위한 추가 연구로 이어질 수 있으며, 또한 외상성 뇌 손상 및 바이러스 감염에 대한 잠재력도 탐구할 수 있습니다.
부실라민은 n-아세틸시스테인(NAC)보다 더 효과적인 항산화제로서, 발작 활동에 대한 효능을 높이면서 NAC와 관련된 항응고 및 출혈 사건의 위험을 줄일 수 있는 잠재력이 있습니다. 이 연구는 현재의 항경련제 치료에 중요 한국 GABA(A) 수용체의 신경 보호에 내재하고 있습니다.
Revive Therapeutics (OTCQB: RVVTF) a fourni une mise à jour sur leur étude de recherche évaluant Bucillamine comme traitement potentiel pour l'exposition aux agents neurotoxiques, menée en partenariat avec le Defence R&D Canada – Suffield Research Centre (DRDC). Le premier ensemble d'essais sur des animaux, incluant des contrôles sur soman et des sujets prétraités avec Bucillamine, a été complété, le DRDC analysant désormais les données sur la baisse de la régulation des récepteurs GABA.
Si les résultats s'avèrent significatifs, Revive et DRDC discuteront des voies de développement futures. Des résultats prometteurs pourraient conduire à d'autres études pour obtenir l'approbation de la FDA et de Santé Canada pour l'utilisation de la Bucillamine dans le traitement de l'intoxication par des agents neurotoxiques ou des pesticides organophosphorés, ainsi qu'à explorer son potentiel en cas de traumatisme crânien dû à des forces concussives et des infections virales.
La Bucillamine, étant un antioxydant plus efficace que le N-acétylcystéine (NAC), pourrait potentiellement fournir une plus grande efficacité contre l'activité convulsive tout en réduisant les risques d'événements hémorragiques et anticoagulants associés à la NAC. La recherche se concentre sur la neuroprotection des récepteurs GABA(A), qui sont importants pour les thérapies anticonvulsivantes actuelles.
Revive Therapeutics (OTCQB: RVVTF) hat ein Update zu ihrer Forschungsstudie gegeben, die Bucillamin als potenzielle Behandlung bei einer Exposition gegenüber Nervengiften bewertet. Diese Studie wird in Zusammenarbeit mit dem Defence R&D Canada – Suffield Research Centre (DRDC) durchgeführt. Der erste Satz von Tierversuchen, einschließlich Soman-Kontrollen und zuvor mit Bucillamin behandelten Probanden, wurde abgeschlossen, und das DRDC analysiert nun die Daten zur Herunterregulierung der GABA-Rezeptoren.
Wenn sich die Ergebnisse als signifikant herausstellen, werden Revive und DRDC über zukünftige Entwicklungswege diskutieren. Vielversprechende Ergebnisse könnten zu weiteren Studien führen, um die Genehmigungen der FDA und von Health Canada für die Verwendung von Bucillamin zur Behandlung von Nervengift- oder Organophosphat-Pestizidvergiftungen sowie zur Erforschung seines Potenzials bei traumatischen Hirnverletzungen durch stumpfe Gewalt und Virusinfektionen zu erhalten.
Bucillamin, das ein effektiveres Antioxidans als N-Acetylcystein (NAC) ist, könnte potenziell eine erhöhte Wirksamkeit gegen Anfallsaktivität bieten und gleichzeitig das Risiko von Blutgerinnungs- und Blutungsereignissen im Zusammenhang mit NAC verringern. Die Forschung konzentriert sich auf den Neuroprotektion der GABA(A)-Rezeptoren, die für die derzeitigen antikonvulsiven Therapien wichtig sind.
- Initial phase of animal trials completed
- Bucillamine shows potential advantages over NAC with better antioxidant properties and lower bleeding risks
- Multiple potential applications including nerve agent exposure, pesticide poisoning, and traumatic brain injury
- Results are still pending and effectiveness is not yet proven
- Multiple regulatory approvals required from FDA and Health Canada
- Further studies needed before any commercial application
TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury.
The DRDC have the first set of animals (soman controls and bucillamine pretreated) completed and is now performing the assays looking at GABA receptor downregulation. Over the next few weeks data will be collected and analysed for effect size. Should the data show significant effects, Revive and the DRDC will discuss on the future development path. The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and explore its potential for traumatic brain injury caused by concussive or explosive forces and viral infections.
Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.
Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the year ended June 30, 2024 ("MD&A"), dated October 25, 2024, which is available on the Company's profile at www.sedarplus.ca.
FAQ
What is the current status of Revive Therapeutics' (RVVTF) Bucillamine study for nerve agent exposure?
How does Bucillamine compare to NAC in treating nerve agent exposure?
What are the potential applications for Bucillamine being studied by RVVTF?
What regulatory approvals does RVVTF need for Bucillamine's nerve agent treatment?
What is the main objective of RVVTF's Bucillamine research project?
